82 related articles for article (PubMed ID: 8938565)
21. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Portielje JE; Lamers CH; Kruit WH; Sparreboom A; Bolhuis RL; Stoter G; Huber C; Gratama JW
Clin Cancer Res; 2003 Jan; 9(1):76-83. PubMed ID: 12538454
[TBL] [Abstract][Full Text] [Related]
22. Soluble cytokine receptors in renal vasculitis and lupus nephritis.
Tesar V; Jirsa M; Zima T; Kalousová M; Bartunková J; Stejskalová A; Dostál C; Zabka J
Med Sci Monit; 2002 Jan; 8(1):BR24-9. PubMed ID: 11782670
[TBL] [Abstract][Full Text] [Related]
23. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
[TBL] [Abstract][Full Text] [Related]
24. Protection against cartilage and bone destruction by systemic interleukin-4 treatment in established murine type II collagen-induced arthritis.
Joosten LA; Lubberts E; Helsen MM; Saxne T; Coenen-de Roo CJ; Heinegård D; van den Berg WB
Arthritis Res; 1999; 1(1):81-91. PubMed ID: 11056663
[TBL] [Abstract][Full Text] [Related]
25. A pilot study of intralymphatic interleukin-2. I. Cytotoxic and surface marker changes of peripheral blood lymphocytes.
Shau H; Isacescu V; Ibayashi Y; Tokuda Y; Golub SH; Fahey JL; Sarna GP
J Biol Response Mod; 1990 Feb; 9(1):71-80. PubMed ID: 2319261
[TBL] [Abstract][Full Text] [Related]
26. Effects of the administration of high-dose interleukin-2 on immunoregulatory cell subsets in patients with advanced melanoma and renal cell cancer.
van der Vliet HJ; Koon HB; Yue SC; Uzunparmak B; Seery V; Gavin MA; Rudensky AY; Atkins MB; Balk SP; Exley MA
Clin Cancer Res; 2007 Apr; 13(7):2100-8. PubMed ID: 17404092
[TBL] [Abstract][Full Text] [Related]
27. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
[TBL] [Abstract][Full Text] [Related]
28. Interleukin-2 based immunotherapy in patients with metastatic renal cell carcinoma.
Donskov F
Dan Med Bull; 2007 Nov; 54(4):249-65. PubMed ID: 18208677
[TBL] [Abstract][Full Text] [Related]
29. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
Bukowski RM; Olencki T; Gunn H; McLain D; Budd GT; Sandstrom K; Tuason L; Redovan C; Rayman P; Tubbs R; Resta D; Elson P; Finke J
Clin Cancer Res; 1996 Feb; 2(2):347-57. PubMed ID: 9816178
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-1 receptor antagonist, soluble tumor necrosis factor-alpha receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-beta1a.
Perini P; Tiberio M; Sivieri S; Facchinetti A; Biasi G; Gallo P
Eur Cytokine Netw; 2000 Mar; 11(1):81-6. PubMed ID: 10705303
[TBL] [Abstract][Full Text] [Related]
31. A two-part phase I trial of high-dose interleukin 2 in combination with soluble (Chinese hamster ovary) interleukin 1 receptor.
McDermott DF; Trehu EG; Mier JW; Sorce D; Rand W; Ronayne L; Kappler K; Clancy M; Klempner M; Atkins MB
Clin Cancer Res; 1998 May; 4(5):1203-13. PubMed ID: 9607578
[TBL] [Abstract][Full Text] [Related]
32. Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients.
Nieken J; Mulder NH; Buter J; Vellenga E; Limburg PC; Piers DA; de Vries EG
Blood; 1995 Aug; 86(3):900-5. PubMed ID: 7542502
[TBL] [Abstract][Full Text] [Related]
33. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate.
Seitz M; Zwicker M; Villiger PM
J Rheumatol; 2003 Jan; 30(1):28-35. PubMed ID: 12508386
[TBL] [Abstract][Full Text] [Related]
34. Signal through gp130 activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors.
Kimura T; Wang J; Minamiguchi H; Fujiki H; Harada S; Okuda K; Kaneko H; Yokota S; Yasukawa K; Abe T; Sonoda Y
Stem Cells; 2000; 18(6):444-52. PubMed ID: 11072033
[TBL] [Abstract][Full Text] [Related]
35. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial.
Stouthard JM; Goey H; de Vries EG; de Mulder PH; Groenewegen A; Pronk L; Stoter G; Sauerwein HP; Bakker PJ; Veenhof CH
Br J Cancer; 1996 Mar; 73(6):789-93. PubMed ID: 8611381
[TBL] [Abstract][Full Text] [Related]
37. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study.
van Gameren MM; Willemse PH; Mulder NH; Limburg PC; Groen HJ; Vellenga E; de Vries EG
Blood; 1994 Sep; 84(5):1434-41. PubMed ID: 8068939
[TBL] [Abstract][Full Text] [Related]
38. Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: results of a phase II study.
Schuler M; Bruntsch U; Späth-Schwalbe E; Schrezenmeier H; Peschel C; Färber L; Burger KJ; Leissner J; Huber C; Aulitzky WE
Eur J Cancer; 1998 Apr; 34(5):754-6. PubMed ID: 9713286
[TBL] [Abstract][Full Text] [Related]
39. Neopterin, soluble IL-2 receptor and IL-6 secretion during IL-2 cancer immunotherapy: prognostic significance in relation to IL-12 variations.
Lissoni P; Barni S; Di Felice G; Majorca F; Fumagalli L
Int J Biol Markers; 1997; 12(3):134-6. PubMed ID: 9479598
[No Abstract] [Full Text] [Related]
40. Role of interleukin-6 in the paraneoplastic inflammatory syndrome associated with renal-cell carcinoma.
Blay JY; Rossi JF; Wijdenes J; Menetrier-Caux C; Schemann S; Négrier S; Philip T; Favrot M
Int J Cancer; 1997 Jul; 72(3):424-30. PubMed ID: 9247285
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]